SLC7A11 and neoplasm: Administration of 65 (10 mg/kg, ip) to mice with grafted MDA‐MB‐231 cells accordingly reduced the tumor burden, and cotreatment with 14 (200 mg/kg) prevented the upregulation of KFL4 and SLC7A11 and exhibited superior antitumoral activity.